Lilly

08 May 1989
News

Executive Summary

Licenses Cytogen's proprietary monoclonal antibody-based technology for the site-specific delivery of vinca alkaloid compounds and other cancer therapies patented by Lilly in return for an unspecified licensing fee, an equity investment and royalty payments. Lilly will be responsible for clinicals and seeking FDA approval. Firms have completed animal testing of possible product formulations. Agreement will complement monoclonal antibody research activities at Lilly's Hybritech subsidiary.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS015553

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS015553

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Lilly

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert